

















Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16
Published in Health and Fitness on Tuesday, March 8th 2011 at 10:50 GMT by Market Wire

PASADENA, Calif.--([ BUSINESS WIRE ])--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the Roth 23rd Annual OC Growth Stock Conference at 11:30 a.m. Pacific time on Wednesday, March 16, 2011. The conference is being held at the Ritz Carlton in Laguna Niguel, California.
Investors attending the conference are encouraged to schedule a one-on-one meeting at the conference with Arrowheada™s CEO Dr. Christopher Anzalone by contacting [ conference@roth.com ], or Brandi Floberg at [ arrowres@tpg-ir.com ] or 212-481-2050.
The presentation will be webcast live and can be accessed by visiting the Company's website at [ www.arrowheadresearch.com ]. A replay of the presentation will be archived on the Arrowhead website for 90 days.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit [ http://www.arrowheadresearch.com ].